BioSpace News Archive

Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced progress towards its value creation strategy of expanding global reimbursement for the Neovasc Reducer™ (“Reducer”)

Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report its first quarter 2021 financial results after market close on Wednesday, May 5, 2021. The company will host a conference call and webcast at 4:30 PM ET that day to discuss these financial results and provide an update on clinical and corporate activities.

VigiLanz, a clinical surveillance company, today released findings from their third annual hospital patient safety survey

AnchorDx, a world-leading developer of cancer screening and early detection solutions, together with renowned thoracic experts from 14 top-tier hospitals in China, jointly published a clinical research paper entitled “Accurate Diagnosis of Pulmonary Nodules Using a Non-invasive DNA Methylation Test”

Precirix NV, a clinical-stage biotechnology company developing novel radiopharmaceuticals in oncology, and Evergreen Theragnostics, Inc., a radiopharmaceutical contract manufacturer, announced that the companies have entered into an agreement whereby Evergreen will provide US-based manufacturing for Precirix’s lead product candidate, CAM-H2.

PPD, Inc., a leading global contract research organization, is expanding its Athlone, Ireland, GMP laboratory, significantly increasing the size of its current facility and adding cell and gene therapy testing to the operation’s portfolio of services.

Illumina, Inc. (NASDAQ: ILMN) has committed US $60 million in sequencing capabilities to a global pathogen genomics initiative, in partnership with the Bill & Melinda Gates Foundation and other public and private entities

At the intersection of inclusion and mentorship, Nitin Rai, managing director at Elevate Capital, and Brenna Rauw, director at XXcelerate Fund and owner of 12Bridge, are teaming up to discuss and create interactive conversations.

POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients, announced today that the U.S. Nuclear Regulatory Commission (NRC) has issued a Materials License for its new production facility located in Indianapolis, Indiana.

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, in collaboration with its development partner Servier, an independent international pharmaceutical company, today announced that longer-term follow-up data from Allogene’s dose escalation Phase 1 ALPHA study of ALLO-501 in relapsed/refractory non-Hodgkin lymphoma